BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16:453-463. [PMID: 19302335 DOI: 10.1111/j.1365-2893.2009.01117.x] [Cited by in Crossref: 185] [Cited by in F6Publishing: 193] [Article Influence: 15.4] [Reference Citation Analysis]
Number Citing Articles
1 MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015;5:a021410. [PMID: 25934461 DOI: 10.1101/cshperspect.a021410] [Cited by in Crossref: 114] [Cited by in F6Publishing: 89] [Article Influence: 19.0] [Reference Citation Analysis]
2 Wang Y, Shi JF, Wang L, Yan Y, Yao H, Dai M, Chen T, Qu C. Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China. Int J Infect Dis 2019;78:130-9. [PMID: 30466898 DOI: 10.1016/j.ijid.2018.08.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Chaudhary K, Poirion OB, Lu L, Garmire LX. Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer. Clin Cancer Res. 2018;24:1248-1259. [PMID: 28982688 DOI: 10.1158/1078-0432.ccr-17-0853] [Cited by in Crossref: 272] [Cited by in F6Publishing: 137] [Article Influence: 68.0] [Reference Citation Analysis]
4 Ahn SM, Jang SJ, Shim JH, Kim D, Hong SM, Sung CO, Baek D, Haq F, Ansari AA, Lee SY. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology. 2014;60:1972-1982. [PMID: 24798001 DOI: 10.1002/hep.27198] [Cited by in Crossref: 215] [Cited by in F6Publishing: 194] [Article Influence: 30.7] [Reference Citation Analysis]
5 Lutchman GA, Nguyen MA. Screening for Hepatocellular Carcinoma After HBsAg Clearance Age Before Cirrhosis?: Age Before Cirrhosis? Journal of Clinical Gastroenterology 2011;45:4-5. [DOI: 10.1097/mcg.0b013e3181faf0d1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Yan Y, Wang L, He J, Liu P, Lv X, Zhang Y, Xu X, Zhang L, Zhang Y. Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation. Biomedicine & Pharmacotherapy 2017;88:395-402. [DOI: 10.1016/j.biopha.2017.01.077] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
7 Şirin N, Elmas L, Seçme M, Dodurga Y. Investigation of possible effects of apigenin, sorafenib and combined applications on apoptosis and cell cycle in hepatocellular cancer cells. Gene 2020;737:144428. [PMID: 32045658 DOI: 10.1016/j.gene.2020.144428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
8 Huang Y, Wu H, Xue R, Liu T, Dong L, Yao J, Zhang Y, Shen X. Identification of N-glycosylation in hepatocellular carcinoma patients' serum with a comparative proteomic approach. PLoS One 2013;8:e77161. [PMID: 24143209 DOI: 10.1371/journal.pone.0077161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
9 Luo Z, Xie Y, Deng M, Zhou X, Ruan B. Prevalence of hepatitis B in the southeast of China: a population-based study with a large sample size. Eur J Gastroenterol Hepatol. 2011;23:695-700. [PMID: 21617533 DOI: 10.1097/meg.0b013e328347322b] [Cited by in Crossref: 45] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
10 Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78-88. [PMID: 24457013 DOI: 10.1016/j.semcancer.2014.01.004] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 13.0] [Reference Citation Analysis]
11 Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37. [PMID: 24367230 DOI: 10.2147/hmer.s16316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 120] [Article Influence: 4.3] [Reference Citation Analysis]
12 Mitchell T, Armstrong GL, Hu DJ, Wasley A, Painter JA. The increasing burden of imported chronic hepatitis B--United States, 1974-2008. PLoS One. 2011;6:e27717. [PMID: 22163270 DOI: 10.1371/journal.pone.0027727] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
13 Freitas N, Lukash T, Dudek M, Litwin S, Menne S, Gudima SO. Capacity of a natural strain of woodchuck hepatitis virus, WHVNY, to induce acute infection in naive adult woodchucks. Virus Res 2015;205:12-21. [PMID: 25979221 DOI: 10.1016/j.virusres.2015.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
14 Qin C, Gao Y, Li J, Huang C, He S. Predictive effects of preoperative serum CA125 and AFP levels on post-hepatectomy survival in patients with hepatitis B-related hepatocellular carcinoma. Oncol Lett 2021;21:487. [PMID: 33968203 DOI: 10.3892/ol.2021.12748] [Reference Citation Analysis]
15 Akcay IM, Katrinli S, Ozdil K, Doganay GD, Doganay L. Host genetic factors affecting hepatitis B infection outcomes: Insights from genome-wide association studies. World J Gastroenterol. 2018;24:3347-3360. [PMID: 30122875 DOI: 10.3748/wjg.v24.i30.3347] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
16 Zhong R, Liu L, Tian Y, Wang Y, Tian J, Zhu BB, Chen W, Qian JM, Zou L, Xiao M. Genetic variant in SWI/SNF complexes influences hepatocellular carcinoma risk: a new clue for the contribution of chromatin remodeling in carcinogenesis. Sci Rep. 2014;4:4147. [PMID: 24556940 DOI: 10.1038/srep04147] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
17 Westin J, Aleman S, Castedal M, Duberg A, Eilard A, Fischler B, Kampmann C, Lindahl K, Lindh M, Norkrans G, Stenmark S, Weiland O, Wejstål R. Management of hepatitis B virus infection, updated Swedish guidelines. Infectious Diseases 2020;52:1-22. [DOI: 10.1080/23744235.2019.1675903] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
18 Cheng N, Chen D, Lou B, Fu J, Wang H. A biosensing method for the direct serological detection of liver diseases by integrating a SERS-based sensor and a CNN classifier. Biosens Bioelectron 2021;186:113246. [PMID: 33965791 DOI: 10.1016/j.bios.2021.113246] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Mok Y, Son DK, Yun YD, Jee SH, Samet JM. γ-Glutamyltransferase and cancer risk: The Korean cancer prevention study. Int J Cancer 2016;138:311-9. [PMID: 26111622 DOI: 10.1002/ijc.29659] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
20 Li B, Shao Q, Ji D, Li F, Guo X, Chen G. Combined aberrant expression of N-Myc downstream-regulated gene 2 and CD24 is associated with disease-free survival and overall survival in patients with hepatocellular carcinoma. Diagn Pathol 2014;9:209. [PMID: 25338637 DOI: 10.1186/s13000-014-0209-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
21 Lao X, Wang X, Liu Y, Lu Y, Yang D, Liu M, Zhang X, Rong C, Qin X, Li S. Association of Paraoxonase 1 Gene Polymorphisms With the Risk of Hepatitis B Virus-related Liver Diseases in a Guangxi Population: A Case-control Study. Medicine (Baltimore) 2015;94:e2179. [PMID: 26632904 DOI: 10.1097/MD.0000000000002179] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
22 Kim J, Yu SJ, Park B, Cheong HS, Pasaje CFA, Bae JS, Lee H, Shin HD, Kim YJ. <i>TGFBR3</i> Polymorphisms and Its Haplotypes Associated with Chronic Hepatitis B Virus Infection and Age of Hepatocellular Carcinoma Occurrence. Dig Dis 2011;29:278-83. [DOI: 10.1159/000327559] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
23 Chon YE, Jung KS, Kim MJ, Choi JY, An C, Park JY, Ahn SH, Kim BK, Kim SU, Park H, Hwang SK, Rim KS, Han KH, Kim DY. Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. Aliment Pharmacol Ther 2018;47:1201-12. [PMID: 29492988 DOI: 10.1111/apt.14578] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
24 Webster NJG. Alternative RNA Splicing in the Pathogenesis of Liver Disease. Front Endocrinol (Lausanne) 2017;8:133. [PMID: 28680417 DOI: 10.3389/fendo.2017.00133] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
25 Croagh CMN, Bell SJ, Locarnini S, Desmond PV. Assessment of chronic hepatitis B: the importance of hepatitis B virus DNA testing: HBV DNA in assessment of CHB. Internal Medicine Journal 2012;42:170-5. [DOI: 10.1111/j.1445-5994.2011.02435.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
26 Lyu H, Lee D, Chung YH, Kim JA, Lee JH, Jin YJ, Park W, Mathews P, Jaffee E, Zheng L. Synergistic effects of A1896, T1653 and T1762/A1764 mutations in genotype c2 hepatitis B virus on development of hepatocellular carcinoma. J Viral Hepat. 2013;20:219-224. [PMID: 23383661 DOI: 10.1111/j.1365-2893.2012.01654.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
27 Zhong R, Tian J, Fu M, Ma S, Liu L, Li J, Shen N, Ke J, Yang Y, Gong Y, Zhu Y, Wang Y, Gong J, Chang J, Lei P, Cheng X, Huang K, Shen G, Miao X. LINC01149 variant modulates MICA expression that facilitates hepatitis B virus spontaneous recovery but increases hepatocellular carcinoma risk. Oncogene 2020;39:1944-56. [PMID: 31754211 DOI: 10.1038/s41388-019-1117-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
28 Pollicino T, Saitta C. Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol. 2014;20:5951-5961. [PMID: 24876718 DOI: 10.3748/wjg.v20.i20.5951] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
29 Xie BH, He X, Hua RX, Zhang B, Tan GS, Xiong SQ, Liu LS, Chen W, Yang JY, Wang XN, Li HP. Mir-765 promotes cell proliferation by downregulating INPP4B expression in human hepatocellular carcinoma. Cancer Biomark. 2016;16:405-413. [PMID: 27062697 DOI: 10.3233/cbm-160579] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 7.6] [Reference Citation Analysis]
30 Liao SF, Yang HI, Lee MH, Chen CJ, Lee WC. Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan. PLoS One. 2012;7:e34779. [PMID: 22506050 DOI: 10.1371/journal.pone.0034779] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
31 Zhang Y, Zheng D, Xiong Y, Xue C, Chen G, Yan B, Ye Q. miR-202 suppresses cell proliferation in human hepatocellular carcinoma by downregulating LRP6 post-transcriptionally. FEBS Lett 2014;588:1913-20. [PMID: 24704686 DOI: 10.1016/j.febslet.2014.03.030] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
32 Chen CP, Haas-kogan D. Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics. Expert Review of Molecular Diagnostics 2014;10:883-95. [DOI: 10.1586/erm.10.76] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
33 Yan W, Zhu Z, Pan F, Huang A, Dai GH. Overexpression of c-kit(CD117), relevant with microvessel density, is an independent survival prognostic factor for patients with HBV-related hepatocellular carcinoma. Onco Targets Ther 2018;11:1285-92. [PMID: 29563807 DOI: 10.2147/OTT.S157545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Sitia G, Iannacone M, Guidotti LG. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol. 2013;59:1135-1138. [PMID: 23742914 DOI: 10.1016/j.jhep.2013.05.040] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 6.3] [Reference Citation Analysis]
35 Xu Y, Qi Y, Luo J, Yang J, Xie Q, Deng C, Su N, Wei W, Shi D, Xu F, Li X, Xu P. Hepatitis B Virus X Protein Stimulates Proliferation, Wound Closure and Inhibits Apoptosis of HuH-7 Cells via CDC42. Int J Mol Sci 2017;18:E586. [PMID: 28282856 DOI: 10.3390/ijms18030586] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
36 Zhang L, Xie XY, Chen Y, Ge NL, Chen RX, Gan YH, Zhang BH, Wang YH, Ren ZG. Hepatitis B surface antigen predicts recurrence after radiofrequency ablation in patients with low hepatitis B virus loads. Medicine (Baltimore) 2017;96:e9377. [PMID: 29384914 DOI: 10.1097/MD.0000000000009377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
37 Wang H, Cao G, Fu J, Lv G. Hepatitis Viruses and Hepatoma. In: Bast RC, Hait WN, Kufe DW, Weichselbaum RR, Holland JF, Croce CM, Piccart-gebart M, Wang H, Hong WK, Pollock RE, editors. Holland-Frei Cancer Medicine. Hoboken: John Wiley & Sons, Inc.; 2016. pp. 1-6. [DOI: 10.1002/9781119000822.hfcm031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Wang K, Pei H, Huang B, Yang RL, Wu HY, Zhu X, Zhu L. Overexpression of Fc receptor-like 1 associated with B-cell activation during hepatitis B virus infection. Braz J Med Biol Res 2012;45:1112-8. [PMID: 22892829 DOI: 10.1590/s0100-879x2012007500130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
39 Liu H, Zhao P, Jin X, Zhao Y, Chen Y, Yan T, Wang J, Wu L, Sun Y. A 9‑lncRNA risk score system for predicting the prognosis of patients with hepatitis B virus‑positive hepatocellular carcinoma. Mol Med Rep 2019;20:573-83. [PMID: 31115573 DOI: 10.3892/mmr.2019.10262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
40 Ben Ari Z, Weitzman E, Safran M. Oncogenic Viruses and Hepatocellular Carcinoma. Clinics in Liver Disease 2015;19:341-60. [DOI: 10.1016/j.cld.2015.01.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
41 Xu Y, Ge K, Lu J, Huang J, Wei W, Huang Q. MicroRNA-493 suppresses hepatocellular carcinoma tumorigenesis through down-regulation of anthrax toxin receptor 1 (ANTXR1) and R-Spondin 2 (RSPO2). Biomed Pharmacother 2017;93:334-43. [PMID: 28651234 DOI: 10.1016/j.biopha.2017.06.047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
42 Yeganeh B, Rezaei Moghadam A, Alizadeh J, Wiechec E, Alavian SM, Hashemi M, Geramizadeh B, Samali A, Bagheri Lankarani K, Post M, Peymani P, Coombs KM, Ghavami S. Hepatitis B and C virus-induced hepatitis: Apoptosis, autophagy, and unfolded protein response. World J Gastroenterol 2015;21:13225-39. [PMID: 26715805 DOI: 10.3748/wjg.v21.i47.13225] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
43 Yin J, Xie J, Zhang H, Shen Q, Han L, Lu W, Han Y, Li C, Ni W, Wang H. Significant association of different preS mutations with hepatitis B-related cirrhosis or hepatocellular carcinoma. J Gastroenterol. 2010;45:1063-1071. [PMID: 20419326 DOI: 10.1007/s00535-010-0253-1.] [Reference Citation Analysis]
44 Liu X, Wan X, Li Z, Lin C, Zhan Y, Lu X. Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin Chem Lab Med. 2011;49:1311-1316. [PMID: 21663469 DOI: 10.1515/cclm.2011.640] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
45 Zhang R, Guo H, Xu J, Li B, Liu YJ, Cheng C, Zhou C, Zhao Y, Liu Y. Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding. Oncotarget 2016;7:60609-22. [PMID: 27542264 DOI: 10.18632/oncotarget.11300] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
46 Nam JY, Lee JH, Kim HY, Kim JE, Lee DH, Chang Y, Cho H, Yoo JJ, Lee M, Cho YY, Cho Y, Cho E, Yu SJ, Kim YJ, Yoon JH. Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients. PLoS One 2017;12:e0166188. [PMID: 28099520 DOI: 10.1371/journal.pone.0166188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Du Y, Han X, Ding YB, Yin JH, Cao GW. Prediction and prophylaxis of hepatocellular carcinoma occurrence and postoperative recurrence in chronic hepatitis B virus-infected subjects. World J Gastroenterol 2016;22:6565-72. [PMID: 27547000 DOI: 10.3748/wjg.v22.i29.6565] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Yin J, Liang P, Chen G, Wang F, Cui F, Liang X, Zhuang G. Tenofovir prophylaxis for preventing mother-to-child hepatitis B virus transmission in China: A cost-effectiveness analysis. Int J Infect Dis 2020;95:118-24. [PMID: 32205288 DOI: 10.1016/j.ijid.2020.03.036] [Reference Citation Analysis]
49 Yu L, Guo X, Zhang P, Qi R, Li Z, Zhang S. Cyclic adenosine monophosphate-responsive element-binding protein activation predicts an unfavorable prognosis in patients with hepatocellular carcinoma. Onco Targets Ther 2014;7:873-9. [PMID: 24926200 DOI: 10.2147/OTT.S63594] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
50 Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis. 2012;16:e82-e88. [PMID: 22178658 DOI: 10.1016/j.ijid.2011.10.009] [Cited by in Crossref: 105] [Cited by in F6Publishing: 97] [Article Influence: 10.5] [Reference Citation Analysis]
51 Hsu A, Lai CL, Yuen MF. Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. Curr Hepat Rep. 2011;10:106-111. [PMID: 21654908 DOI: 10.1007/s11901-011-0094-] [Reference Citation Analysis]
52 Burman BE, Mukhtar NA, Toy BC, Nguyen TT, Chen AH, Yu A, Berman P, Hammer H, Chan D, McCulloch CE, Khalili M. Hepatitis B management in vulnerable populations: gaps in disease monitoring and opportunities for improved care. Dig Dis Sci 2014;59:46-56. [PMID: 24052195 DOI: 10.1007/s10620-013-2870-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
53 Huang GL, Li BK, Zhang MY, Zhang HZ, Wei RR, Yuan YF, Shi M, Chen XQ, Huang L, Li AH, Huang BJ, Li HH, Wang HY. LOH analysis of genes around D4S2964 identifies ARD1B as a prognostic predictor of hepatocellular carcinoma. World J Gastroenterol 2010;16:2046-54. [PMID: 20419844 DOI: 10.3748/wjg.v16.i16.2046] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
54 Tamaki Y, Nakade Y, Yamauchi T, Makino Y, Yokohama S, Okada M, Aso K, Kanamori H, Ohashi T, Sato K, Nakao H, Haneda M, Yoneda M. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol. 2013;48:491-503. [PMID: 22886508 DOI: 10.1007/s00535-012-0651-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
55 Arora A, Sharma P, Tyagi P, Singla V, Arora V, Bansal N, Toshniwal J, Kumar A. Hepatitis B Virus Infection can Cause Hepatocellular Carcinoma in Less Advanced Liver Cirrhosis: A Comparative Study of 142 Patients from North India. J Clin Exp Hepatol 2013;3:288-95. [PMID: 25755516 DOI: 10.1016/j.jceh.2013.08.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
56 Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C, Lin D. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011;50:136-42. [DOI: 10.1002/mc.20712] [Cited by in Crossref: 379] [Cited by in F6Publishing: 365] [Article Influence: 34.5] [Reference Citation Analysis]
57 Yin J, Ji Z, Liang P, Wu Q, Cui F, Wang F, Liang X, Zhuang G. The doses of 10 μg should replace the doses of 5 μg in newborn hepatitis B vaccination in China: A cost-effectiveness analysis. Vaccine 2015;33:3731-8. [PMID: 26057138 DOI: 10.1016/j.vaccine.2015.05.082] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
58 Jin M, Yu Q, Liu Y, Xu W, Fu X, Ji B. Safety and Efficacy of Physical Thermal Ablation Combined Sorafenib for Hepatocellular Carcinoma: A Meta-analysis. J Clin Transl Hepatol 2021;9:149-59. [PMID: 34007796 DOI: 10.14218/JCTH.2020.00125] [Reference Citation Analysis]
59 Shih YL, Kuo CC, Yan MD, Lin YW, Hsieh CB, Hsieh TY. Quantitative methylation analysis reveals distinct association between PAX6 methylation and clinical characteristics with different viral infections in hepatocellular carcinoma. Clin Epigenetics. 2016;8:41. [PMID: 27110298 DOI: 10.1186/s13148-016-0208-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
60 Yu Y, He Z, Cao Y, Tang H, Huang F. TAGLN2, a novel regulator involved in Hepatitis B virus transcription and replication. Biochem Biophys Res Commun 2016;477:1051-8. [PMID: 27402267 DOI: 10.1016/j.bbrc.2016.07.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
61 Wang H, Wang AH, Gressner OA, Fang M, Gu X, Ji Q, Cheng SQ, Shen F, Gao CF. Association between HBV Pre-S mutations and the intracellular HBV DNAs in HBsAg-positive hepatocellular carcinoma in China. Clin Exp Med 2015;15:483-91. [PMID: 25501679 DOI: 10.1007/s10238-014-0321-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
62 Tong HV, Song le H, Hoan NX, Cuong BK, Sy BT, Son HA, Quyet D, Binh VQ, Kremsner PG, Bock CT, Velavan TP, Toan NL. Soluble MICB protein levels and platelet counts during hepatitis B virus infection and response to hepatocellular carcinoma treatment. BMC Infect Dis 2015;15:25. [PMID: 25626490 DOI: 10.1186/s12879-015-0754-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
63 [DOI: 10.1101/114892] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
64 Nguyen K, Jack K, Sun W. Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases 2015;4:E1. [PMID: 28933381 DOI: 10.3390/diseases4010001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
65 Singla B, Chakraborti A, Sharma BK, Kapil S, Chawla YK, Arora SK, Das A, Dhiman RK, Duseja A. Levels of hepatitis B virus replicative intermediate in serum samples of chronic hepatitis B patients. Mol Biol Rep 2014;41:4689-96. [PMID: 24706057 DOI: 10.1007/s11033-014-3339-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
66 Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol. 2009;15:5761-5769. [PMID: 19998495 DOI: 10.3748/wjg.15.5761.] [Reference Citation Analysis]
67 Zhang H, Yao M, Wu W, Qiu L, Sai W, Yang J, Zheng W, Huang J, Yao D. Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma. Tumour Biol. 2015;36:9373-9383. [PMID: 26109000 DOI: 10.1007/s13277-015-3678-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
68 Chen MS Jr, Dang J. Hepatitis B among Asian Americans: Prevalence, progress, and prospects for control. World J Gastroenterol. 2015;21:11924-11930. [PMID: 26576081 DOI: 10.3748/wjg.v21.i42.11924] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
69 Yang HJ, Jiang JH, Yang YT, Guo Z, Li JJ, Liu XH, Lu F, Zeng FH, Ye JS, Zhang KL, Chen NZ, Xiang BD, Li LQ. Stratified aspartate aminotransferase-to-platelet ratio index accurately predicts survival in hepatocellular carcinoma patients undergoing curative liver resection. Tumour Biol 2017;39:1010428317695944. [PMID: 28351330 DOI: 10.1177/1010428317695944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
70 Holness G, Carriero DC, Dieterich DT. Hepatitis B therapies and antiviral resistance detection and management. Expert Review of Gastroenterology & Hepatology 2014;3:693-9. [DOI: 10.1586/egh.09.64] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Wan DW, Tzimas D, Smith JA, Kim S, Araujo J, David R, Lobach I, Sarpel U. Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States. Am J Gastroenterol. 2011;106:1994-2000. [PMID: 21912436 DOI: 10.1038/ajg.2011.302] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
72 Chakladar J, Wong LM, Kuo SZ, Li WT, Yu MA, Chang EY, Wang XQ, Ongkeko WM. The Liver Microbiome Is Implicated in Cancer Prognosis and Modulated by Alcohol and Hepatitis B. Cancers (Basel) 2020;12:E1642. [PMID: 32575865 DOI: 10.3390/cancers12061642] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
73 Li L, Wang H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 2016;379:191-197. [PMID: 26213370 DOI: 10.1016/j.canlet.2015.07.018] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 13.0] [Reference Citation Analysis]
74 El-serag HB, Lechel A, Rudolph KL. Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 142-56. [DOI: 10.1016/b978-1-4377-0881-3.00010-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
75 Vutien P, Trinh HN, Garcia RT, Nguyen HA, Levitt BS, Nguyen K, da Silveira E, Daugherty T, Ahmed A, Garcia G. Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients. Clin Gastroenterol Hepatol. 2014;12:1363-1370. [PMID: 24342744 DOI: 10.1016/j.cgh.2013.11.036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
76 Agarwal AK, Sen S, Banerjee D, Srivastava R, Praharaj AK. Distribution of hepatitis B virus genotype and cancer predicting precore and basal core promoter mutations. Med J Armed Forces India 2015;71:225-32. [PMID: 26288490 DOI: 10.1016/j.mjafi.2015.04.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
77 Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, Cao GW. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol. 2011;17:4258-4270. [PMID: 22090781 DOI: 10.3748/wjg.v17.i38.4258.] [Reference Citation Analysis]
78 Do AL, Wong CR, Nguyen LH, Nguyen VG, Trinh H, Nguyen MH. Hepatocellular Carcinoma Incidence in Noncirrhotic Patients With Chronic Hepatitis B and Patients With Cirrhosis of All Etiologies. Journal of Clinical Gastroenterology 2014;48:644-9. [DOI: 10.1097/mcg.0000000000000015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
79 Shen D, Zheng J, Cui X, Chen Y, He Q, Lv R, Li Z, Zhao S. Analysis of cholyglycine acid as a biomarker for the early diagnosis of liver disease by fluorescence polarization immunoassay. Sensors and Actuators B: Chemical 2018;256:846-52. [DOI: 10.1016/j.snb.2017.10.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 7.3] [Reference Citation Analysis]
80 Hsu YC, Tseng CH, Huang YT, Yang HI. Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective. Semin Liver Dis 2021;41:285-97. [PMID: 34161993 DOI: 10.1055/s-0041-1730924] [Reference Citation Analysis]
81 Yang Y, Wen F, Li J, Zhang P, Yan W, Hao P, Xia F, Bi F, Li Q. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver Int 2015;35:2147-54. [PMID: 25676812 DOI: 10.1111/liv.12805] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
82 Ng J, Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon 2012;12:e7635. [PMID: 23233865 DOI: 10.5812/hepatmon.7635] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
83 Liu S, Xie J, Yin J, Zhang H, Zhang Q, Pu R, Li C, Ni W, Wang H, Cao G. A matched case-control study of hepatitis B virus mutations in the preS and core promoter regions associated independently with hepatocellular carcinoma. J Med Virol. 2011;83:45-53. [PMID: 21108338 DOI: 10.1002/jmv.21829] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
84 Shi Y, Wang J, Wang Y, Wang A, Guo H, Wei F, Mehta SR, Espitia S, Smith DM, Liu L, Zhang Y, Chen D. A novel mutant 10Ala/Arg together with mutant 144Ser/Arg of hepatitis B virus X protein involved in hepatitis B virus-related hepatocarcinogenesis in HepG2 cell lines. Cancer Lett 2016;371:285-91. [PMID: 26706415 DOI: 10.1016/j.canlet.2015.12.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
85 Kim JM, Kwon CH, Joh JW, Park JB, Lee JH, Kim SJ, Paik SW, Park CK, Yoo BC. Differences between hepatocellular carcinoma and hepatitis B virus infection in patients with and without cirrhosis. Ann Surg Oncol 2014;21:458-65. [PMID: 24132624 DOI: 10.1245/s10434-013-3302-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
86 Nguyen VG, Wan K, Trinh HN, Li J, Zhang JQ, Nguyen MH. Chronic hepatitis B treatment eligibility and actual treatment rates in patients in community gastroenterology and primary care settings. J Clin Gastroenterol 2015;49:145-9. [PMID: 25014233 DOI: 10.1097/MCG.0000000000000132] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
87 Feng H, Li B, Li Z, Wei Q, Ren L. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer 2021;21:401. [PMID: 33849479 DOI: 10.1186/s12885-021-08138-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123-135. [PMID: 23344543 DOI: 10.1038/nrc3449] [Cited by in Crossref: 505] [Cited by in F6Publishing: 463] [Article Influence: 63.1] [Reference Citation Analysis]
89 Liu K, Choi J, Le A, Yip TC, Wong VW, Chan SL, Chan HL, Nguyen MH, Lim YS, Wong GL. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. Aliment Pharmacol Ther 2019;50:1037-48. [PMID: 31524304 DOI: 10.1111/apt.15499] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
90 Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol. 2009;15:5761-5769. [PMID: 19998495 DOI: 10.3748/wjg.15.5761] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 98] [Article Influence: 8.4] [Reference Citation Analysis]
91 Jiang N, Chen WJ, Zhang JW, Xu C, Zeng XC, Zhang T, Li Y, Wang GY. Downregulation of miR-432 activates Wnt/β-catenin signaling and promotes human hepatocellular carcinoma proliferation. Oncotarget 2015;6:7866-79. [PMID: 25797263 DOI: 10.18632/oncotarget.3492] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
92 Liégeois F, Boyer S, Eymard-Duvernay S, Carrieri P, Kouanfack C, Domyeum J, Maradan G, Ducos J, Mpoudi-Ngolé E, Spire B, Delaporte E, Kuaban C, Vidal L, Laurent C; EVOLCAM study group. Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM). BMC Infect Dis 2020;20:49. [PMID: 31941464 DOI: 10.1186/s12879-020-4784-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Chen P, Yu C, Ruan B, Yang S, Ren J, Xu W, Luo Z, Li L. Prevalence of hepatitis B in insular regions of southeast China: a community-based study. PLoS One. 2013;8:e56444. [PMID: 23437134 DOI: 10.1371/journal.pone.0056444] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
94 Li Y, Hu Y, Xiao J, Liu G, Li X, Zhao Y, Tan H, Shi H, Cheng D. Investigation of SP94 Peptide as a Specific Probe for Hepatocellular Carcinoma Imaging and Therapy. Sci Rep 2016;6:33511. [PMID: 27649935 DOI: 10.1038/srep33511] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
95 Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, Cao GW. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol. 2011;17:4258-4270. [PMID: 22090781 DOI: 10.3748/wjg.v17.i38.4258] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
96 Datta S, Ghosh A, Dasgupta D, Ghosh A, Roychoudhury S, Roy G, Das S, Das K, Gupta S, Basu K, Basu A, Datta S, Chowdhury A, Banerjee S. Novel point and combo-mutations in the genome of hepatitis B virus-genotype D: characterization and impact on liver disease progression to hepatocellular carcinoma. PLoS One 2014;9:e110012. [PMID: 25333524 DOI: 10.1371/journal.pone.0110012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
97 Mutimer DJ, Oo YH. Hepatitis B. Medicine 2011;39:545-9. [DOI: 10.1016/j.mpmed.2011.06.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
98 Liu WB, Wu JF, Du Y, Cao GW. Cancer Evolution-Development: experience of hepatitis B virus-induced hepatocarcinogenesis. Curr Oncol 2016;23:e49-56. [PMID: 26966413 DOI: 10.3747/co.23.2836] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
99 Zhang Z, Xu L, Wang Z. Screening serum biomarkers for early primary hepatocellular carcinoma using a phage display technique. J Clin Lab Anal 2011;25:402-8. [PMID: 22086793 DOI: 10.1002/jcla.20491] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
100 Yurdacan B, Egeli U, Eskiler GG, Eryilmaz I, Cecener G, Tunca B. The role of usnic acid-induced apoptosis and autophagy in hepatocellular carcinoma. Hum Exp Toxicol 2019;38:201-15. [DOI: 10.1177/0960327118792052] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
101 Lee D, Lyu H, Chung YH, Kim JA, Mathews P, Jaffee E, Zheng L, Yu E, Lee YJ, Ryu SH. Genomic change in hepatitis B virus associated with development of hepatocellular carcinoma. World J Gastroenterol. 2016;22:5393-5399. [PMID: 27340355 DOI: 10.3748/wjg.v22.i23.5393] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
102 Feng D, Wang M, Hu J, Li S, Zhao S, Li H, Liu L. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. Ann Transl Med 2020;8:553. [PMID: 32411776 DOI: 10.21037/atm.2020.02.116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
103 Zheng H, Zou AE, Saad MA, Wang XQ, Kwok JG, Korrapati A, Li P, Kisseleva T, Wang-Rodriguez J, Ongkeko WM. Alcohol-dysregulated microRNAs in hepatitis B virus-related hepatocellular carcinoma. PLoS One. 2017;12:e0178547. [PMID: 28562643 DOI: 10.1371/journal.pone.0178547] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
104 Lee DW, Yim HJ, Seo YS, Na SK, Kim SY, Suh SJ, Hyun JJ, Jung SW, Jung YK, Koo JS, Kim JH, Yeon JE, Lee SW, Byun KS, Um SH. Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study. Liver Int. 2019;39:1109-1119. [PMID: 30972935 DOI: 10.1111/liv.14117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
105 Chen C, Lee W, Yang H, Chang H, Jen C, Iloeje UH, Su J, Hsiao CK, Wang L, You S, Lu S, Chen C. Changes in Serum Levels of HBV DNA and Alanine Aminotransferase Determine Risk for Hepatocellular Carcinoma. Gastroenterology 2011;141:1240-1248.e2. [DOI: 10.1053/j.gastro.2011.06.036] [Cited by in Crossref: 152] [Cited by in F6Publishing: 136] [Article Influence: 15.2] [Reference Citation Analysis]
106 Xia L, Song M, Sun M, Wang F, Yang C. Circular RNAs as Biomarkers for Cancer. Adv Exp Med Biol. 2018;1087:171-187. [PMID: 30259366 DOI: 10.1007/978-981-13-1426-1_14] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
107 Hsu A, Lai CL, Yuen MF. Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. Curr Hepat Rep. 2011;10:106-111. [PMID: 21654908 DOI: 10.1007/s11901-011-0094-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
108 Rawat S, Clippinger AJ, Bouchard MJ. Modulation of apoptotic signaling by the hepatitis B virus X protein. Viruses. 2012;4:2945-2972. [PMID: 23202511 DOI: 10.3390/v4112945] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
109 Fu J, Wang H. Precision diagnosis and treatment of liver cancer in China. Cancer Letters 2018;412:283-8. [DOI: 10.1016/j.canlet.2017.10.008] [Cited by in Crossref: 107] [Cited by in F6Publishing: 89] [Article Influence: 35.7] [Reference Citation Analysis]
110 Mathai AM, Alexander J, Kuo F, Torbenson M, Swanson PE, Yeh MM. Type II ground-glass hepatocytes as a marker of hepatocellular carcinoma in chronic hepatitis B. Human Pathology 2013;44:1665-71. [DOI: 10.1016/j.humpath.2013.01.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
111 Vergara Gómez M, Miquel Planas M, Gil Prades M, Dalmau Obrador B, Casas Rodrigo M, Sanchez Delgado J, Bella MR, Puig Domingo J. [Rapid progression of hepatocellular carcinoma after surgery: apropos of a case and review of the literature]. Gastroenterol Hepatol 2010;33:569-73. [PMID: 20627456 DOI: 10.1016/j.gastrohep.2010.03.008] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
112 Xu Y, Chen J, Wang H, Zheng H, Feng D, Zhang A, Leng J, Duan W, Yang Z, Chen M, Shi X, Cai S, Ji W, Jiang K, Zhang W, Chen Y, Gu W, Dong J, Lu S. Perioperative and long-term outcomes of liver resection for hepatitis B virus-related hepatocellular carcinoma without versus with hepatic inflow occlusion: study protocol for a prospective randomized controlled trial. Trials 2016;17:492. [PMID: 27724929 DOI: 10.1186/s13063-016-1621-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
113 Yao Y, Shen Y, Shao H, Liu Y, Ji Y, Du G, Ye X, Huang P, Chen H. Polymorphisms of RIG-I-like receptor influence HBV clearance in Chinese Han population. J Med Virol 2021;93:4957-65. [PMID: 33783003 DOI: 10.1002/jmv.26969] [Reference Citation Analysis]
114 Trung NT, Hai LT, Giang DP, Hoan PQ, Binh MT, Hoan NX, Toan NL, Meyer CG, Velavan TP, Bang MH, Song LH. No expression of HBV-human chimeric fusion transcript (HBx-LINE1) among Vietnamese patients with HBV-associated hepatocellular carcinoma. Ann Hepatol 2019;18:404-5. [PMID: 31036498 DOI: 10.1016/j.aohep.2019.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
115 Strasser SI, Thompson AJ, Roberts SK, George J; Clinical Cases in Hepatitis 2018 Steering Committee. Clinical Cases in Hepatitis: Towards improving liver disease management in Australia. J Gastroenterol Hepatol 2019;34 Suppl 1:5-15. [PMID: 31282011 DOI: 10.1111/jgh.14720] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 Yang T, Lu JH, Zhai J, Lin C, Yang GS, Zhao RH, Shen F, Wu MC. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol. 2012;38:683-691. [PMID: 22621971 DOI: 10.1016/j.ejso.2012.04.010] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 5.3] [Reference Citation Analysis]
117 Cui Z, Yu X, Guo L, Wei Y, Zheng S, Li W, Chen P, Zhu J, Peng J. Combined analysis of serum alpha-fetoprotein and MAGE-A3-specific cytotoxic T lymphocytes in peripheral blood for diagnosis of hepatocellular carcinoma. Dis Markers. 2013;35:915-923. [PMID: 24427779 DOI: 10.1155/2013/907394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
118 Jin YJ, Chung YH, Kim JA, Park WH, Lee D, Seo DD, Ryu SH, Jang MK, Yu E, Lee YJ. Factors predisposing metastatic tumor antigen 1 overexpression in hepatitis B virus associated hepatocellular carcinoma. Dig Dis Sci. 2012;57:2917-2923. [PMID: 22777614 DOI: 10.1007/s10620-012-2296-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
119 Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010;42 Suppl 3:S206-14. [PMID: 20547305 DOI: 10.1016/S1590-8658(10)60507-5] [Cited by in Crossref: 347] [Cited by in F6Publishing: 183] [Article Influence: 31.5] [Reference Citation Analysis]
120 McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis. 2010;14:461-476. [PMID: 20638025 DOI: 10.1016/j.cld.2010.05.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
121 Benharroch D, Osyntsov L. Infectious diseases are analogous with cancer. Hypothesis and implications. J Cancer 2012;3:117-21. [PMID: 22408684 DOI: 10.7150/jca.3977] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
122 Li G, Zhang W, Gong L, Huang X. MicroRNA 125a-5p Inhibits Cell Proliferation and Induces Apoptosis in Hepatitis B Virus-Related Hepatocellular Carcinoma by Downregulation of ErbB3. Oncol Res 2019;27:449-58. [PMID: 28800792 DOI: 10.3727/096504017X15016337254623] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
123 Sun Y, Wang Y, Li M, Cheng K, Zhao X, Zheng Y, Liu Y, Lei S, Wang L. Long-term trends of liver cancer mortality by gender in urban and rural areas in China: an age-period-cohort analysis. BMJ Open. 2018;8:e020490. [PMID: 29439081 DOI: 10.1136/bmjopen-2017-020490] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
124 Tian S, Hui X, Fan Z, Li Q, Zhang J, Yang X, Ma X, Huang B, Chen D, Chen H. Suppression of hepatocellular carcinoma proliferation and hepatitis B surface antigen secretion with interferon-λ1 or PEG-interferon-λ1. FASEB J 2014;28:3528-39. [PMID: 24769671 DOI: 10.1096/fj.14-250704] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
125 Fatima S, Lee NP, Luk JM. Dickkopfs and Wnt/β-catenin signalling in liver cancer. World J Clin Oncol 2011;2:311-25. [PMID: 21876852 DOI: 10.5306/wjco.v2.i8.311] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
126 Yurdacan B, Egeli U, Guney Eskiler G, Eryilmaz IE, Cecener G, Tunca B. Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid. Journal of Pharmacy and Pharmacology 2019;71:1119-32. [DOI: 10.1111/jphp.13097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
127 Cao G. Exploring risk factors of hepatitis B virus-associated hepatocellular carcinoma: prospective verse retrospective studies. J Gastroenterol. 2011;46:125-127. [PMID: 20820819 DOI: 10.1007/s00535-010-0314-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
128 Xiao Y, Najeeb RM, Ma D, Yang K, Zhong Q, Liu Q. Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms. J Exp Clin Cancer Res 2019;38:458. [PMID: 31703591 DOI: 10.1186/s13046-019-1444-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
129 Van Tong H, Hoan NX, Binh MT, Quyen DT, Meyer CG, Song LH, Toan NL, Velavan TP. Interferon-stimulated gene 20 kDa protein serum levels and clinical outcome of hepatitis B virus-related liver diseases. Oncotarget 2018;9:27858-71. [PMID: 29963243 DOI: 10.18632/oncotarget.25559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
130 Liang T, Mok K, Liu S, Huang S, Chou N, Tsai C, Chen I, Yeh M, Chen Y, Wang B. Hepatitis B Genotype C Correlated with Poor Surgical Outcomes for Hepatocellular Carcinoma. Journal of the American College of Surgeons 2010;211:580-6. [DOI: 10.1016/j.jamcollsurg.2010.06.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
131 Gu X, Fu M, Ding Y, Ni H, Zhang W, Zhu Y, Tang X, Xiong L, Li J, Qiu L, Xu J, Zhu J. TIMP-3 expression associates with malignant behaviors and predicts favorable survival in HCC. PLoS One 2014;9:e106161. [PMID: 25171061 DOI: 10.1371/journal.pone.0106161] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
132 Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F, Esposito A, Ruggeri ZM, Chisari FV, Iannacone M, Guidotti LG. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA. 2012;109:E2165-E2172. [PMID: 22753481 DOI: 10.1073/pnas.1209182109] [Cited by in Crossref: 192] [Cited by in F6Publishing: 189] [Article Influence: 21.3] [Reference Citation Analysis]
133 Cao TW, Geng CA, Ma YB, Zhang XM, Zhou J, Tao YD, Chen JJ. Chemical constituents of Swertia mussotii and their anti-hepatitis B virus activity. Fitoterapia. 2015;102:15-22. [PMID: 25665940 DOI: 10.1016/j.fitote.2015.01.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
134 Rawat S, Bouchard MJ. The hepatitis B virus (HBV) HBx protein activates AKT to simultaneously regulate HBV replication and hepatocyte survival. J Virol. 2015;89:999-1012. [PMID: 25355887 DOI: 10.1128/JVI.02440-14] [Cited by in Crossref: 63] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
135 Wang H, Fang M, Gu X, Ji Q, Li D, Cheng SQ, Shen F, Gao CF. The intracellular HBV DNAs as novel and sensitive biomarkers for the clinical diagnosis of occult HBV infection in HBeAg negative hepatocellular carcinoma in China. PLoS One. 2014;9:e107162. [PMID: 25229710 DOI: 10.1371/journal.pone.0107162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
136 Li ZL, Yan WT, Zhang J, Zhao YJ, Lau WY, Mao XH, Zeng YY, Zhou YH, Gu WM, Wang H, Chen TH, Han J, Xing H, Wu H, Li C, Wang MD, Wu MC, Shen F, Yang T. Identification of Actual 10-Year Survival After Hepatectomy of HBV-Related Hepatocellular Carcinoma: a Multicenter Study. J Gastrointest Surg 2019;23:288-96. [PMID: 30334177 DOI: 10.1007/s11605-018-4006-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
137 Gu X, Ji Q, Wang H, Jiang M, Yang J, Fang M, Wang M, Gao C. Genetic variants of mannose-binding lectin 2 gene influence progression and prognosis of patients with hepatitis B virus infection in China. Clin Res Hepatol Gastroenterol 2016;40:614-21. [PMID: 26857650 DOI: 10.1016/j.clinre.2015.12.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
138 Shen SL, Fu SJ, Chen B, Kuang M, Li SQ, Hua YP, Liang LJ, Guo P, Hao Y, Peng BG. Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection. Ann Surg Oncol. 2014;21:3802-3809. [PMID: 24849520 DOI: 10.1245/s10434-014-3771-x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 9.4] [Reference Citation Analysis]
139 Sarkar M, Stewart S, Yu A, Chen MS, Nguyen TT, Khalili M. Hepatocellular carcinoma screening practices and impact on survival among hepatitis B-infected Asian Americans. J Viral Hepat 2012;19:594-600. [PMID: 22762144 DOI: 10.1111/j.1365-2893.2011.01577.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
140 Shen N, Wang P, Li Y, Zhu Y, Gong Y, Zhong R, Lu Y, Cheng L. Nonreceptor protein tyrosine phosphatases (NRPTPs) gene family associates with the risk of hepatocellular carcinoma in a Chinese hepatitis B virus-related subjects. Mol Carcinog 2020;59:980-8. [PMID: 32484301 DOI: 10.1002/mc.23228] [Reference Citation Analysis]
141 Bagga S, Bouchard MJ. Cell cycle regulation during viral infection. Methods Mol Biol 2014;1170:165-227. [PMID: 24906315 DOI: 10.1007/978-1-4939-0888-2_10] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 11.5] [Reference Citation Analysis]
142 Cao K, Gong H, Qiu Z, Wen Q, Zhang B, Tang T, Zhou X, Cao T, Wang B, Shi H, Wang R. Hepatitis B virus X protein reduces the stability of Nrdp1 to up-regulate ErbB3 in hepatocellular carcinoma cells. Tumour Biol 2016;37:10375-82. [PMID: 26846102 DOI: 10.1007/s13277-016-4936-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
143 Rossi L, Zoratto F, Papa A, Iodice F, Minozzi M, Frati L, Tomao S. Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol. 2010;2:348-359. [PMID: 21160806 DOI: 10.4251/wjgo.v2.i9.348] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
144 Tong HV, Toan NL, Song LH, Bock CT, Kremsner PG, Velavan TP. Hepatitis B virus-induced hepatocellular carcinoma: functional roles of MICA variants. J Viral Hepat. 2013;20:687-698. [PMID: 24010643 DOI: 10.1111/jvh.12089] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
145 Yang YT, Jiang JH, Yang HJ, Wu ZJ, Xiao ZM, Xiang BD. The lymphocyte-to-monocyte ratio is a superior predictor of overall survival compared to established biomarkers in HCC patients undergoing liver resection. Sci Rep 2018;8:2535. [PMID: 29416061 DOI: 10.1038/s41598-018-20199-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
146 Tong MJ, Rosinski AA, Huynh CT, Raman SS, Lu DSK. Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. Hepatol Commun 2017;1:595-608. [PMID: 29404481 DOI: 10.1002/hep4.1047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
147 Nagaoki Y, Hyogo H, Aikata H, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Chayama K. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res. 2012;42:368-375. [PMID: 22151896 DOI: 10.1111/j.1872-034x.2011.00929.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
148 Hua H, Zhang H, Kong Q, Wang J, Jiang Y. Complex roles of the old drug aspirin in cancer chemoprevention and therapy. Med Res Rev 2019;39:114-45. [PMID: 29855050 DOI: 10.1002/med.21514] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
149 Mkhwanazi NK, de Koning CB, van Otterlo WAL, Ariatti M, Singh M. PEGylation potentiates hepatoma cell targeted liposome-mediated in vitro gene delivery via the asialoglycoprotein receptor. Z Naturforsch C J Biosci 2017;72:293-301. [PMID: 28063265 DOI: 10.1515/znc-2016-0172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
150 Ji J, Gu X, Fang M, Zhao Y, Yi C, Wang A, Gao C. Expression of alpha 1,6-fucosyltransferase 8 in hepatitis B virus-related hepatocellular carcinoma influences tumour progression. Dig Liver Dis. 2013;45:414-421. [PMID: 23352314 DOI: 10.1016/j.dld.2012.12.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
151 Koshiol J, Liu Z, O'Brien TR, Hildesheim A. Beasley's 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention. Cancer Epidemiol 2018;53:195-9. [PMID: 29396075 DOI: 10.1016/j.canep.2018.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
152 Casper M, Grünhage F, Lammert F. Cancer risk in chronic hepatitis B: Do genome-wide association studies hit the mark? Hepatology 2011;53:1390-2. [PMID: 21480342 DOI: 10.1002/hep.24241] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
153 Cho HJ, Cheong JY. Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Int J Mol Sci 2021;22:8011. [PMID: 34360777 DOI: 10.3390/ijms22158011] [Reference Citation Analysis]
154 Fung J, Lai CL, Seto WK, Wong DK, Yuen MF. Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. J Viral Hepat. 2011;18:738-744. [PMID: 20659306 DOI: 10.1111/j.1365-2893.2010.01355.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
155 Li Z, Zheng W, Li H, Li C, Gong Z. Synergistic Induction of Potential Warburg Effect in Zebrafish Hepatocellular Carcinoma by Co-Transgenic Expression of Myc and xmrk Oncogenes. PLoS One 2015;10:e0132319. [PMID: 26147004 DOI: 10.1371/journal.pone.0132319] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
156 Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014;60:2099-2108. [PMID: 25164003 DOI: 10.1002/hep.27406] [Cited by in Crossref: 592] [Cited by in F6Publishing: 513] [Article Influence: 84.6] [Reference Citation Analysis]
157 Zhang X, Zhu S, Zhu W, Li A, Zhu N. A Newly Identified Natural Splice Variant ASN Enhances Hepatitis B Virus Amplification. Viral Immunol 2016;29:27-32. [PMID: 26501888 DOI: 10.1089/vim.2015.0044] [Reference Citation Analysis]
158 Guo Y, Yang Y, Bai Q, Huang Z, Wang Z, Cai D, Li S, Man X, Shi X. Cost-utility analysis of newborn hepatitis B immunization in Beijing. Hum Vaccin Immunother 2021;17:1196-204. [PMID: 33016814 DOI: 10.1080/21645515.2020.1807812] [Reference Citation Analysis]
159 Tong HV, Thomas Bock C, Velavan TP. Genetic insights on host and hepatitis B virus in liver diseases. Mutation Research/Reviews in Mutation Research 2014;762:65-75. [DOI: 10.1016/j.mrrev.2014.06.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
160 Chen YL, Xu QP, Guo F, Guan WH. MicroRNA-302d downregulates TGFBR2 expression and promotes hepatocellular carcinoma growth and invasion. Exp Ther Med. 2017;13:681-687. [PMID: 28352351 DOI: 10.3892/etm.2016.3970] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
161 Xu W, Guo W, Lu P, Ma D, Liu L, Yu F. Identification of an autophagy-related gene signature predicting overall survival for hepatocellular carcinoma. Biosci Rep 2021;41:BSR20203231. [PMID: 33351066 DOI: 10.1042/BSR20203231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Luo X, Wang Y, Shen A, Deng H, Ye M. Relationship between the rs2596542 polymorphism in the MICA gene promoter and HBV/HCV infection-induced hepatocellular carcinoma: a meta-analysis. BMC Med Genet 2019;20:142. [PMID: 31419949 DOI: 10.1186/s12881-019-0871-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
163 Robotin MC, Kansil MQ, George J, Howard K, Tipper S, Levy M, Phung N, Penman AG. Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation. BMC Health Serv Res 2010;10:215. [PMID: 20663140 DOI: 10.1186/1472-6963-10-215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
164 Heo NY, Lee HC, Park YK, Park JW, Lim YS, Kim KM, Shim JH, Lee YJ. Lack of association between hepatitis B virus pre-S mutations and recurrence after surgical resection in hepatocellular carcinoma. J Med Virol. 2013;85:589-596. [PMID: 23296476 DOI: 10.1002/jmv.23502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
165 Xie J, Zhao J, Yin J, Zhang Q, Pu R, Lu W, Zhang H, Wang H, Cao G. Association of novel mutations and heplotypes in the preS region of hepatitis B virus with hepatocellular carcinoma. Front Med China 2010;4:419-29. [DOI: 10.1007/s11684-010-0160-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
166 Li MX, Zhao H, Bi XY, Li ZY, Huang Z, Han Y, Zhou JG, Zhao JJ, Zhang YF, Cai JQ. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma: Validation in a Chinese cohort. Hepatol Res. 2017;47:731-741. [PMID: 27558521 DOI: 10.1111/hepr.12796] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
167 Ge L, Wan H, Tang S, Chen H, Li J, Zhang K, Zhou B, Fei J, Wu S, Zeng X. Novel caffeoylquinic acid derivatives from Lonicera japonica Thunb. flower buds exert pronounced anti-HBV activities. RSC Adv 2018;8:35374-85. [DOI: 10.1039/c8ra07549b] [Cited by in Crossref: 16] [Article Influence: 5.3] [Reference Citation Analysis]
168 Lee M, Zhu L, Wang MQ, Wei Z, Tan Y, Nguyen MT, Ogunwobi OO, Ma GX. Psychosocial Predictors of HBV Screening Behavior among Vietnamese Americans. Am J Health Behav 2017;41:561-70. [PMID: 28760178 DOI: 10.5993/AJHB.41.5.5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
169 Chi H, Chen S, Lin S, Tsai C, Chuang W, Lin Y, Huang Y, Tsai M, Yeh C, Lin K. Thyroid hormone protects hepatocytes from HBx-induced carcinogenesis by enhancing mitochondrial turnover. Oncogene 2017;36:5274-84. [DOI: 10.1038/onc.2017.136] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
170 Yu Y, Ai J, Zhang W. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2017;11:925-37. [PMID: 28661190 DOI: 10.1080/17474124.2017.1343665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
171 Xie N, Chen X, Zhang T, Liu B, Huang C. Using proteomics to identify the HBx interactome in hepatitis B virus: how can this inform the clinic? Expert Rev Proteomics. 2014;11:59-74. [PMID: 24308553 DOI: 10.1586/14789450.2014.861745] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
172 Niu J, Lin Y, Liu P, Yu Y, Su C, Wang X. Microarray analysis on the lncRNA expression profile in male hepatocelluar carcinoma patients with chronic hepatitis B virus infection. Oncotarget 2016;7:76169-80. [PMID: 27769059 DOI: 10.18632/oncotarget.12732] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
173 Liu WT, Lu X, Tang GH, Ren JJ, Liao WJ, Ge PL, Huang JF. LncRNAs expression signatures of hepatocellular carcinoma revealed by microarray. World J Gastroenterol. 2014;20:6314-6321. [PMID: 24876753 DOI: 10.3748/wjg.v20.i20.6314] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
174 Cai L, Cai X. Up-regulation of miR-9 expression predicate advanced clinicopathological features and poor prognosis in patients with hepatocellular carcinoma. Diagn Pathol. 2014;9:1000. [PMID: 25552204 DOI: 10.1186/s13000-014-0228-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
175 Fan H, Zhang Q, Zhao X, Lv P, Liu M, Tang H. Transcriptomic profiling of long non-coding RNAs in hepatitis B virus-related hepatocellular carcinoma. Oncotarget 2017;8:65421-34. [PMID: 29029442 DOI: 10.18632/oncotarget.18897] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
176 Xu C, Zhou W, Wang Y, Qiao L. Hepatitis B virus-induced hepatocellular carcinoma. Cancer Lett. 2014;345:216-222. [PMID: 23981576 DOI: 10.1016/j.canlet.2013.08.035] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 11.0] [Reference Citation Analysis]
177 Venook AP, Papandreou C, Furuse J, Ladrón de Guevara L. The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. The Oncologist 2010;15:5-13. [DOI: 10.1634/theoncologist.2010-s4-05] [Cited by in Crossref: 575] [Cited by in F6Publishing: 317] [Article Influence: 52.3] [Reference Citation Analysis]
178 Yin J, Xie J, Zhang H, Shen Q, Han L, Lu W, Han Y, Li C, Ni W, Wang H, Cao G. Significant association of different preS mutations with hepatitis B-related cirrhosis or hepatocellular carcinoma. J Gastroenterol 2010;45:1063-71. [DOI: 10.1007/s00535-010-0253-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
179 Cohen C, Holmberg SD, McMahon BJ, Block JM, Brosgart CL, Gish RG, London WT, Block TM. Is chronic hepatitis B being undertreated in the United States? J Viral Hepat. 2011;18:377-383. [PMID: 21143343 DOI: 10.1111/j.1365-2893.2010.01401.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 10.3] [Reference Citation Analysis]
180 Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 342-374.e17. [DOI: 10.1016/b978-0-323-35761-6.00025-0] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
181 Siburian MD, Suriapranata IM, Wanandi SI. Pre-S2 Start Codon Mutation of Hepatitis B Virus Subgenotype B3 Effects on NF-κB Expression and Activation in Huh7 Cell Lines. Viral Immunol 2018;31:362-70. [PMID: 29652648 DOI: 10.1089/vim.2017.0158] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
182 Sitia G. Platelets Promote Liver Immunopathology Contributing to Hepatitis B Virus–Mediated Hepatocarcinogenesis. Seminars in Oncology 2014;41:402-5. [DOI: 10.1053/j.seminoncol.2014.04.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
183 Zhang H, Chen X, Yuan Y. Investigation of the miRNA and mRNA Coexpression Network and Their Prognostic Value in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:8726567. [PMID: 33274225 DOI: 10.1155/2020/8726567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Kim H, Kim K, Yu SJ, Jang ES, Yu J, Cho G, Yoon JH, Kim Y. Development of biomarkers for screening hepatocellular carcinoma using global data mining and multiple reaction monitoring. PLoS One 2013;8:e63468. [PMID: 23717429 DOI: 10.1371/journal.pone.0063468] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
185 Liu Z, Xu Y, Zhang W, Gao X, Luo G, Song H, Liu J, Wang H. Identification of targets of JS-K against HBV-positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics. Sci Rep 2021;11:10381. [PMID: 34001947 DOI: 10.1038/s41598-021-90001-3] [Reference Citation Analysis]
186 Greenstein A, Witherspoon R, Iqbal F, Coleman H. Hepatocellular carcinoma metastasis to the maxilla: a rare case. Aust Dent J 2013;58:373-5. [DOI: 10.1111/adj.12083] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
187 Mitchell T, Armstrong GL, Hu DJ, Wasley A, Painter JA. The increasing burden of imported chronic hepatitis B--United States, 1974-2008. PLoS One. 2011;6:e27717. [PMID: 22163270 DOI: 10.1371/journal.pone.0027717] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 8.4] [Reference Citation Analysis]
188 Du Y, Xie J, Chang W, Han Y, Cao G. Genome-wide association studies: inherent limitations and future challenges. Front Med 2012;6:444-50. [DOI: 10.1007/s11684-012-0225-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
189 Cox NR, Patel K, Tillmann HL. A Rationalized Approach to the Treatment of Patients Infected with Hepatitis B. Mol Diagn Ther 2014;18:203-12. [DOI: 10.1007/s40291-013-0072-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
190 Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish RG, de Man RA, Yu M, Llamoso C, Tang H. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol 2015;21:4644-51. [PMID: 25914474 DOI: 10.3748/wjg.v21.i15.4644] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
191 Yang HJ, Jiang JH, Liu QA, Zhou CM, Du YF, Wu T, Chen NZ, Xiang BD. Preoperative platelet-to-lymphocyte ratio is a valuable prognostic biomarker in patients with hepatocellular carcinoma undergoing curative liver resection. Tumour Biol. 2017;39:1010428317707375. [PMID: 28639906 DOI: 10.1177/1010428317707375] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
192 Kew M. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathologie Biologie 2010;58:273-7. [DOI: 10.1016/j.patbio.2010.01.005] [Cited by in Crossref: 168] [Cited by in F6Publishing: 154] [Article Influence: 15.3] [Reference Citation Analysis]
193 Gracia-sancho J, Caparrós E, Fernández-iglesias A, Francés R. Role of liver sinusoidal endothelial cells in liver diseases. Nat Rev Gastroenterol Hepatol 2021;18:411-31. [DOI: 10.1038/s41575-020-00411-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]